Isavuconazole is a once-daily antifungal, used to treat a wide array of fungal infections. In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss isavuconazole’s properties and the efficacy and safety compared to other treatment options.
The abstract entitled: ‘This Drug for That Bug: Really? An Evidence-Based Discussion of Antimicrobial Activity Relevant to Antimicrobial Stewardship‘ was presented at IDWeek 2022, 19-23 October 2022.
Interviews available in this series:
- What properties of isavuconazole make it a good treatment choice for Candida species? (0:21)
- What does the literature tell us about its efficacy and safety compared to other azoles? (0:50)
Disclosures: Kayla Stover Hielscher has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Fungal Infections
Ibrexafungerp against Mucor strains using time-kill and scanning electron microscopy: ECCMID 2023, Mahmoud Ghannoum
Vulnerable immunocompromised individuals are at risk of opportunistic infections by invasive molds, and available antifungal treatments for these invasive infections are currently restricted. Therefore, a combination of therapies has been proposed as a potential strategy to enhance the effectiveness of treatment outcomes. Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals Cleveland Medical Centre, […]
Antifungal resistance – biofilms, tolerance phenomena, treatment and diagnostics: Mahmoud Ghannoum, ECCMID, 2023
Antifungal resistance is an increasing concern in the treatment of fungal infections, especially when there are already limited options in the treatment paradigm. It was a pleasure to talk with Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Center for Medical Mycology, Cleveland, OH, USA) around the impact of biofilms on antifungal therapy, […]
ECCMID 2023 highlights in fungal infections – diagnostics, treatments and case reports: Mahmoud Ghannoum
Editorial Board member Prof. Mahmoud Ghannoum (Integrated Microbiome Core and Centre for Medical Mycology, Cleveland, OH, USA) joins us to discuss ECCMID 2023 highlights in fungal infections, antifungal therapies, diagnostic approaches, and specific case reports that help advise clinicians in clinical practice. Interviews in this series: Ibrexafungerp against Mucor strains using time-kill and scanning electron […]